Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.
Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.
COVID-19 TESTING
CLINICAL therapeutics
AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market
CANCER dIAGNOSTICS
AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer
The Latest On Our Research
AXIM Biotechnologies is a vertically integrated pharmaceutical research company focused on the development of diagnostic tests for the early detection of cancer, research on proprietary small molecules drugs that not only treat cancer but also block metastasis, and research of novel antibodies for therapeutic and diagnostic uses.
AXIM® Biotechnologies Unveils First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization with the FDA
SAN DIEGO, July 15, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, today announced the development of NeuCovixTM, a rapid...
AXIM® Biotechnologies Appoints Dr. Alim Seit-Nebi as Chief Technology Officer of Subsidiary Sapphire Biotech
SAN DIEGO – June 9, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological research, announced today it has appointed Dr. Alim Seit-Nebi as the Chief Technology...
AXIM® Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009
SAN DIEGO, June 1, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has...